Sino Biopharmaceutical Presents FS222 Phase I Results at ASCO Annual Meeting
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has presented updates from...
Academic conference
Legend Biotech’s Carvykti Shows Durable Responses in Multiple Myeloma Patients Post ASCT
Legend Biotech Corporation (NASDAQ: LEGN) has announced results from the Phase II CARTITUDE-2 Cohort D...
Simcere Pharma’s Suvemcitug Shows Positive Results in Platinum-Resistant Ovarian Cancer Study
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has presented updated data...
Ascentage Pharma’s APG-2449 Shows Positive Results in ROS1 and ALK Positive NSCLC at ASCO 2024
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in Suzhou, has announced a wall poster...
Jacobio Pharma’s KRAS G12C Inhibitor Combo Shows Promising Results in NSCLC at ASCO 2024
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, presented updated data at the...
Innovent Biologics Presents Clinical Data for Pipeline Candidates at ASCO 2024
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, presented updates on several...
Hinova Pharmaceuticals to Present Phase I Data for PROTAC Drug HP518 at ASCO 2024
Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, is poised to present data...
Hinova Pharmaceuticals to Present HP518 Data at ASCO, Marking First-in-Human Trial Milestone
Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, is scheduled to present data...
Chinese Biopharma Companies Set to Showcase Oncology Pipelines at ASCO 2024
A cohort of Chinese biopharmaceutical companies, including Wuhan YZY Biopharma Co., Ltd (HKG: 2496), Suzhou...
Chinese Pharma Companies Set to Showcase Cancer Treatments at ASCO 2024
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31...
Novo Nordisk’s Wegovy Shows Durable Weight Loss and Heart Health in Extended Trials
At the 31st European Congress on Obesity (ECO), Denmark’s pharmaceutical giant Novo Nordisk (CPH: NOVO-B)...
Kelun-Biotech’s RET Inhibitor A400 Advances to Phase II Trial with FDA Approval
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, has announced that its...
Jacobio Pharma’s Glecirasib Shows Promise in Phase II Study for NSCLC Presented at ASCO
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the presentation of...
Sino Biopharmaceutical to Present Phase II Data for Garsorasib at AACR 2024
Sino Biopharmaceutical Ltd. (HKG: 1177) announced that it will present the results of a Phase...
Alphamab Oncology’s JSKN003 Demonstrates Promising Results in Phase I HER2-Targeted Solid Tumor Study
Alphamab Oncology (HKG: 9966) presented compelling data from a Phase I clinical trial of its...
Sichuan Kelun-Biotech Presents Positive Results for Sacituzumab Tirumotecan at AACR 2024
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the presentation of favorable results from...
CARsgen Therapeutics’ CT041 Shows Promising Results in Advanced Solid Tumors at ASCO GI 2024
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the presentation of...
Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) provided updates on the clinical development of its...
Innovent Biologics Presents Positive Clinical Results for Efdamrofusp Alfa and IBI324 at AAO
Innovent Biologics, Inc. (HKG: 1801), a China-based biopharmaceutical company, has published the latest clinical results...
Abbisko Therapeutics to Present CSF-1R Inhibitor ABSK021 Data at CTOS Annual Meeting
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it will present data...